Humanitas Gavazzeni

Running trials

• Recruiting

  BIO|STREAM.CSP Study

  NCT07393009· Biotronik SE & Co. KG· Source

• Not yet recruiting

  Hyperprogression upon cemiplimab alone or with chemotherapy in PD-L1 ≥ 50% NSCLC: a biomarker guided phase 2 trial – HYPERBOLIC study

  2025-521583-35-00· Phase 2· Universita' Vita-salute S. Raffaele· Source

• Active, not recruiting

  A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)

  NCT07005128· Phase 3· Amgen· Source

• Recruiting

  PRospective Observational Study of STereotactic Body rAdiation Therapy With Androgen Deprivation Therapy for Organ-confined High-risk Prostate Cancer: the PROSTAR Trial

  NCT06949254· Istituto Clinico Humanitas· Source

• Recruiting

  LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC

  NCT06216301· Phase 3· NovoCure GmbH· Source

• Recruiting

  IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)

  NCT06112314· Phase 3· Immunocore Ltd· Source

• Recruiting

  A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

  NCT06172478· Phase 2· Daiichi Sankyo· Source

• Active, not recruiting

  MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma

  NCT06097728· Phase 3· AstraZeneca· Source

• Recruiting

  A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma

  NCT06084936· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  TTFields in General Routine Clinical Care in Patients With Pleural Mesothelioma Study

  NCT05538806· NovoCure Ltd.· Source

• Recruiting

  Comparison of the Outcomes of Single vs Multiple Arterial Grafts in Women

  NCT04124120· Weill Medical College of Cornell University· Source

• Active, not recruiting

  Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)

  NCT05024773· Phase 3· Fidia Farmaceutici s.p.a.· Source

• Active, not recruiting

  A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products

  NCT05476926· Hoffmann-La Roche· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer4 recruiting
• Melanoma2 recruiting
• Prostate cancer2 recruiting
• Bladder cancer1 recruiting
• Cervical cancer1 recruiting
• Coronary artery disease1 recruiting
• Endometrial cancer1 recruiting
• Gastric and oesophageal cancer1 recruiting
• Head and neck cancer1 recruiting
• Heart failure1 recruiting
• Mantle cell lymphoma1 recruiting
• Mesothelioma1 recruiting
• Ovarian cancer1 recruiting
• Pancreatic cancer1 recruiting

Closed trials

• Completed

  EmploYEd Antithrombotic Therapies in Patients With Acute Coronary Syndromes HOspitalized in iTalian CCUs

  NCT06316128· Heart Care Foundation· Source

• Completed

  A Study to Observe Demography and the Outcome of Prostate Cancer Patients Treated With 6-month Triptorelin Formulation in Italy

  NCT05759273· Ipsen· Source

• Completed

  Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma

  NCT05218499· Phase 2/3· Boehringer Ingelheim· Source

• Completed

  Evaluation of a Modified Anti-Platelet Therapy Associated With Low-dose DES Firehawk in Acute Myocardial Infarction Patients Treated With Complete Revascularization Strategy

  NCT04753749· MicroPort CRM· Source

• Completed

  Agili-C™ Implant Performance Evaluation

  NCT03299959· Smith & Nephew, Inc.· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Neuroendocrine tumours13 works · 0 trials
• Mesothelioma5 works · 2 trials